RHEUMATOID ARTHRITIS: Developing new oral targeted therapies for RA can be challenging

    loading  Checking for direct PDF access through Ovid

Abstract

The positive results of the phase II programme of fostamatinib, developed to target the spleen tyrosine kinase pathway in rheumatoid arthritis (RA), have not been replicated in phase III. What implications might the results have for the development of other oral inhibitors of intracellular kinases in the treatment of RA?

Related Topics

    loading  Loading Related Articles